EU Seeks Hematology Guidance
Europe aims to create new regulations regarding hematological malignancies.
The EMEA is proposing to create new guidance on hematological malignancies. The agency's idea arises from the recent increased activity in developing new treatments for hematological malignancies, including rare disorders and small target populations. This has led to a rise in applications for marketing authorization, but above all to numerous requests for scientific advice from the agency, prior to submitting an application.
The new guidance will deal with special considerations such as allogeneic stem cell transplantation and its consequences in relation to designation of primary endpoints. It will also take account of the use of molecular techniques in response evaluations, treatments administered with curative or palliative intent, and progression or relapse off-therapy. It will focus on the design of confirmatory studies, and will provide separate discussion of major diagnoses such as the acute leukemias, myelodysplastic syndromes, low and high grade lymphomas, and malignant myeloma. Other, rarer conditions will be covered conceptually. Most of the work will be carried out during this year—and anyone wanting to give their views to the agency is invited to do so until the end of this month.—Peter O'Donnell
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
